Finerenone in chronic kidney disease and type 2 diabetes: the known and the unknown

Kidney Int. 2023 Jan;103(1):30-33. doi: 10.1016/j.kint.2022.09.012.

Abstract

The novel nonsteroidal mineralocorticoid receptor antagonist finerenone has been shown to reduce the risk of kidney and cardiovascular outcomes in patients with type 2 diabetes and chronic kidney disease. In this issue of Kidney International, Bakris et al. present new data on the kidney efficacy of finerenone across subgroups of estimated glomerular filtration rate and urinary albumin-to-creatinine ratio, as well as safety data. We attempt to place these results in context by discussing the benefits and risks of finerenone, as well as the generalizability of the study findings to routine care settings.

Publication types

  • Research Support, Non-U.S. Gov't
  • Comment

MeSH terms

  • Diabetes Mellitus, Type 2* / complications
  • Diabetes Mellitus, Type 2* / drug therapy
  • Diabetes Mellitus, Type 2* / urine
  • Diabetic Nephropathies* / drug therapy
  • Diabetic Nephropathies* / etiology
  • Diabetic Nephropathies* / urine
  • Double-Blind Method
  • Humans
  • Mineralocorticoid Receptor Antagonists / adverse effects
  • Renal Insufficiency, Chronic* / complications
  • Renal Insufficiency, Chronic* / drug therapy

Substances

  • finerenone
  • Mineralocorticoid Receptor Antagonists